Furthermore, two secondary mutations in the kinase domain of the fusion protein EML4-ALK were discovered in non-small-cell lung cancer in tumor cells isolated from a patient during the relapse phase of treatment with the ALK inhibitor PF-02341066 [15]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.